Half-life Estimation of Pertussis-Specific Maternal Antibodies in (Pre)Term Infants After In-Pregnancy Tetanus, Diphtheria, Acellular Pertussis Vaccination.
Tdap
antibody kinetic
half-life estimation
maternal antibodies
pertussis
vaccination in pregnancy
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
11
01
2023
accepted:
06
06
2023
medline:
29
11
2023
pubmed:
7
6
2023
entrez:
7
6
2023
Statut:
ppublish
Résumé
To reduce the risk of pertussis-related morbidity and mortality in early life, an increasing number of countries recommend maternal pertussis vaccination. However, there is limited knowledge about half-lives of vaccine-induced pertussis-specific maternal antibodies, especially in preterm infants, and factors potentially influencing them. We compared 2 different approaches to provide estimates of the half-lives of pertussis-specific maternal antibodies in infants and explored potential effects on the half-life in 2 studies. In the first approach, we estimated the half-lives per child and used these estimates as responses in linear models. In the second approach, we used linear mixed effect models on a log2 transformed scale of the longitudinal data to use the inverse of the time parameter as an estimate for the half-lives. Both approaches provided similar results. The identified covariates partly explain differences in half-life estimates. The strongest evidence we observed was a difference between term and preterm infants, with the preterm infants showing a longer half-life. Among others, a longer interval between vaccination and delivery increases the half-life. Several variables influence the decay speed of maternal antibodies. Both approaches have advantages and disadvantages, while the choice is secondary when assessing the half-life of pertussis-specific antibodies. NCT02408926 and NCT02511327.
Sections du résumé
BACKGROUND
BACKGROUND
To reduce the risk of pertussis-related morbidity and mortality in early life, an increasing number of countries recommend maternal pertussis vaccination. However, there is limited knowledge about half-lives of vaccine-induced pertussis-specific maternal antibodies, especially in preterm infants, and factors potentially influencing them.
METHODS
METHODS
We compared 2 different approaches to provide estimates of the half-lives of pertussis-specific maternal antibodies in infants and explored potential effects on the half-life in 2 studies. In the first approach, we estimated the half-lives per child and used these estimates as responses in linear models. In the second approach, we used linear mixed effect models on a log2 transformed scale of the longitudinal data to use the inverse of the time parameter as an estimate for the half-lives.
RESULTS
RESULTS
Both approaches provided similar results. The identified covariates partly explain differences in half-life estimates. The strongest evidence we observed was a difference between term and preterm infants, with the preterm infants showing a longer half-life. Among others, a longer interval between vaccination and delivery increases the half-life.
CONCLUSIONS
CONCLUSIONS
Several variables influence the decay speed of maternal antibodies. Both approaches have advantages and disadvantages, while the choice is secondary when assessing the half-life of pertussis-specific antibodies.
CLINICAL TRIALS REGISTRATION
BACKGROUND
NCT02408926 and NCT02511327.
Identifiants
pubmed: 37285482
pii: 7191798
doi: 10.1093/infdis/jiad212
pmc: PMC10681861
doi:
Substances chimiques
Antibodies, Bacterial
0
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02511327', 'NCT02408926']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1640-1648Subventions
Organisme : Austrian Science Fund
ID : I 6376-B
Organisme : the Research Foundation-Flanders
ID : G004723N
Organisme : Thrasher Research Fund
ID : EWAT 12348
Organisme : FWO
ID : G064015N
Organisme : Sanofi Pasteur
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Curr Opin Immunol. 2019 Aug;59:72-78
pubmed: 31078081
Front Immunol. 2021 Jul 06;12:689394
pubmed: 34305922
Pediatrics. 1984 Jan;73(1):37-42
pubmed: 6318185
Clin Infect Dis. 2014 Aug 15;59(4):560-8
pubmed: 24799324
Vaccine. 2016 Jul 19;34(33):3719-22
pubmed: 27265448
Clin Infect Dis. 2022 Jan 29;74(2):189-198
pubmed: 33971009
J Infect Dis. 1990 Mar;161(3):487-92
pubmed: 2313127
Nat Rev Immunol. 2020 Aug;20(8):464-470
pubmed: 32461674
Pediatr Infect Dis J. 2000 Jul;19(7):635-41
pubmed: 10917222
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S62-5
pubmed: 15876928
J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):11-17
pubmed: 28040688
Pediatr Clin North Am. 2013 Feb;60(1):49-74
pubmed: 23178060
Pediatr Infect Dis J. 2018 Feb;37(2):126-131
pubmed: 28777209
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S236-S243
pubmed: 27838678
Clin Dev Immunol. 2012;2012:985646
pubmed: 22235228
Lancet Infect Dis. 2017 Sep;17(9):974-980
pubmed: 28623146
Stat Med. 2021 Jul 20;40(16):3740-3761
pubmed: 33942345
Vaccine. 2022 Jan 24;40(3):450-458
pubmed: 34949496
Vaccine. 2020 Aug 18;38(37):5955-5961
pubmed: 32709433
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15
pubmed: 25573105
BMC Infect Dis. 2019 Oct 29;19(1):919
pubmed: 31664950
Immunol Res. 2002;25(2):97-113
pubmed: 11999172
Expert Rev Vaccines. 2020 Jul;19(7):621-638
pubmed: 32772755
Vaccine. 2018 Mar 7;36(11):1453-1459
pubmed: 29426663
BMC Infect Dis. 2013 Mar 26;13:151
pubmed: 23530907
J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):118-127
pubmed: 30535079